Industries > Pharma > Chinese Pharmaceutical Market: Forecasts and Outlooks 2014-2024

Chinese Pharmaceutical Market: Forecasts and Outlooks 2014-2024

PUBLISHED: 25 July 2014
PAGES: 305
PRODUCT CODE: PHA0002

Clear
WOOCS 2.2.1
SKU: PHA0002 Categories: , ,

Medical revenues in China – your guide to trends, companies and potentials
What’s the outlook for the Chinese pharma market? Can it sustain high growth? Visiongain’s updated report gives you forecasted revenues there to 2024. That work explains medical and technological trends, prospects and commercial opportunities.

China still holds great potential for medicines and their sales. Our study gives data and predictions for that industry and market. You investigate activities of domestic and international companies – pharma and contract – and assess their environment.

That new analysis shows the most lucrative parts of Chinese healthcare. Read on to explore that market and see what its future could be worth to pharma industries.

Forecasts and other analyses to help you stay ahead for Chinese medical business
Our report gives you revenue predictions to 2024, historical data, growth rates and market shares. It lets you discover business outlooks, including research and development (R&D). You also gain 87 tables, 117 charts and four interviews.

Is finding data on Chinese healthcare proving difficult? Now you can stay ahead in knowledge, benefiting your research, analyses and decisions. The following sections explain.

Sales predictions for the Chinese drug market and its segments – discover potentials
Along with revenue prediction for the overall Chinese pharma market, you see individual forecasting to 2024 for these main submarkets:
• Hospitals
• Retail pharmacies
• Sales via other channels, including over-the-counter (OTC) products
• Small-molecule pharmaceuticals – with sub forecasts for novel and generic drugs
• Biological drugs – with sub forecasts for novel and biosimilar biologics, and for vaccines
• Traditional Chinese medicines (TCM).

Our study also gives individual revenue forecasts to 2024 for sales by therapeutic area:
• Infectious diseases – with sub-forecasts for antibacterial drugs (antibacterials), vaccines and antiviral agents (antivirals)
• Cancer – applications in oncology, anticancer agents
• Cardiovascular disorders – with sub-forecasts for hypertension and dyslipidaemia therapies
• Diabetes
• Respiratory diseases – with sub-forecasts for COPD and asthma treatments
• Autoimmune and inflammatory conditions
• Central nervous system (CNS) disorders – with sub-forecasts for antidepressants and antipsychotics
• Other medical needs (grouped).

Forecasts for contract research (CROs), manufacturing (CMOs) and sales (CSOs)
You also gain individual revenue forecasting to 2024 for these related industries in China:
• Contract medical sales
• Contract research – with sub forecasts for drug discovery and clinical trials outsourcing
• Contract manufacturing and other Chinese pharma production output – with division into drug formulations, active pharmaceutical ingredients (APIs), medical devices, TCM agents, and biologicals.

Also do you understand the changing market – expanding and widening needs? There our report helps you identify potential and find opportunities for revenue growth.

Epidemiological trends – find what patient needs underpin Chinese healthcare
Also for prominent diseases in China discover prevalence and incidences to 2025.
And get our patient flow models for diseases, seeing numbers of patients diagnosed, and treated cases predicted to 2024.

Also explore how companies serve those treatment needs:
• Number of clinical trials registered in China by phase
• Investigational new drug applications by therapy area
• Contract research organisations and their activities
• Chinese companies with innovative pharmaceutical developments
• Biotechnology there, including biomarker testing, regenerative medicine and stem cell research.

You also explore what influences Chinese healthcare industries and markets.

Characteristics, forces and issues affecting the Chinese pharma industry and market
Our report discusses issues, regulations and events affecting Chinese healthcare and related industries from 2014:
• Epidemiological trends, including effects of industrialisation and ageing population
• Sales outlets, distribution channels and product classes most important from 2014
• Manufacturing and R&D, including biotechnology and trends for venture capital
• Healthy China 2020 and other investments and reforms
• Healthcare funding – driving and restraining forces
• Opportunities in treating chronic diseases, including challenges of HIV and hepatitis.

That work also discusses other aspects of medical services and businesses in China, including these developments:
• The Anhui model
• Investment in rural healthcare – high demands needing served
• Growth of contract sales activities and other pharma outsourcing (inc. off-shoring)
• Branded generics – their prospects
• Biosimilar manufacturers – outlooks, including developing bio-betters.

That way you explore technological, economic, social and political trends. You also analyse that market’s strengths, weaknesses, opportunities and threats for businesses. Discover what the future holds.

Leading drugs companies – domestic and foreign – and 2014 market value
What happens next? Our report predicts overall pharma sales in China will reach $97.4bn in 2014, expanding onwards to 2024. See what’s possible.

The study covers these multinationals and others, with discussion of the top 10 big pharma companies operating in China:
• Bayer
• Pfizer
• AstraZeneca
• Roche
• Merck and Co.

Our work also discusses these domestic companies, and other top 30 firms based there:
• Yangtze Pharma
• Harbin Pharmaceutical
• Guangzhou Baiyunshan Pharmaceutical
• Kangmei Pharmaceutical
• Yunnan Baiyao.

In our study you find 320 organisations mentioned. Also you read our interviews with other authorities on Chinese pharma – you see opinions and discussions.

Prospects for product and service sales in China are strong, and from 2014 there will arise many opportunities for companies. Our work shows you the technological, medical and commercial possibilities, helping you succeed. Find that top emerging country’s potential.

Ways Chinese Pharmaceutical Market: Forecasts and Outlooks 2014-2024 helps
In four main ways our investigation helps your work and authority:
Revenues there to 2024 at overall national level and for 39 submarkets – assess outlooks for production, marketing and sales
Epidemiology for China – see treatment needs by disease, assessing data on present and future trends
Prospects for established competitors, rising companies and new entrants – explore results, R&D, news, technologies, activities and outlooks for success
Interviews with authorities on China – scan opinions to help you stay ahead.

Information there found nowhere else, benefiting your knowledge and influence
That work gives independent analysis. There you receive competitive intelligence found only in our report, seeing where technological and financial prospects are most rewarding.

With our study you are less likely to fall behind in knowledge or miss opportunity. See there how you could benefit your research, analyses and decisions, also saving time and getting recognition for technological and commercial insight.

Our knowledge costs only a tiny fraction of potential profits from your understanding and harnessing the vast Chinese market. See its growth potential and find what you can gain.

Getting that report now lets you discover where the money lies in Chinese healthcare
That investigation is for everyone needing analysis of Chinese healthcare industries and markets. There you find data, trends, opportunities and predictions. Stay ahead, then – please get our new report here now.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Download sample pages

Complete the form below to download your free sample pages for Chinese Pharmaceutical Market: Forecasts and Outlooks 2014-2024


Download sample pages

Complete the form below to download your free sample pages for Chinese Pharmaceutical Market: Forecasts and Outlooks 2014-2024


Latest Pharma news

Visiongain Publishes Direct-to-Patient Market Report 2021-2031

Over the last few years, Direct-to-Patient has gained widespread attention. DTP companies offer their customers, who are patients, in this case, all kinds of services.

21 July 2021

READ

Visiongain Publishes Drug Delivery Technologies Market Report 2021-2031

Rising geriatric population, increasing prevalence of chronic and infectious diseases, escalating investment in drug R&D by biopharmaceutical companies, rising demand for advanced drug delivery technologies for chronic treatment are some of the major factors that drive the growth of the global drug delivery technologies market.

20 July 2021

READ

Visiongain Publishes Pharma Contract Sales Market Report 2021-2031

Pharma services companies are widening their service offerings (either organically or inorganically through M&A) to become full-service providers, simplifying their customers’ operations and gaining the maximum share of their outsourcing budgets, driven by the willingness of pharma to reduce the number of outsourcers they use.

14 July 2021

READ

Visiongain Publishes Clinical Trial Supply and Logistics Market for Pharma 2021-2031

Digital innovation in clinical trials and renewed focus on home production will ensure a high growth market for supply chain optimisation.

12 July 2021

READ

Categories